A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Overview

Información sobre este estudio

The purpose of this study is to learn more about volixibat for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

1. Provide freely signed informed consent and assent (as applicable) and be willing to
comply with all study visits and requirements through end of study, including the
follow-up period.

2. Subjects aged ≥12 years for eligible regions; otherwise ≥18 years

3. Confirmed diagnosis of large duct or small duct PSC based on American Association for
the Study of Liver Disease (AASLD) guidelines.

4. Pruritus associated with PSC as assessed by Adult ItchRO.

5. Ursodeoxycholic acid (UDCA) and anti-pruritic medication use will be allowed if
meeting additional criteria.

6. Concomitant Inflammatory Bowel Disease (IBD) is allowed if meeting additional
criteria.

Exclusion Criteria:

1. Pruritus associated with an etiology other than PSC

2. Evidence or clinical suspicion of decompensated cirrhosis, or a history of
decompensation events

3. History of ileostomy or small bowel surgery/resection or other surgeries that may have
disrupted the enterohepatic circulation

4. Evidence, history, or suspicion of other liver diseases

5. Bile duct stent or percutaneous bile duct drain placement, or balloon dilatation
procedure of a stricture within 12 weeks of Screening

6. Exceeding pre-defined biochemical values for alanine aminotransferase/aspartate
aminotransferase (ALT/AST), estimated glomerular filtration rate (eGFR),serum
creatinine (sCr), platelet count, international normalized ratio (INR) and total
bilirubin

7. History of liver transplantation

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 2/28/2024. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

John Eaton, M.D.

Comunícate con nosotros para obtener el estatus más reciente

Contact information:

Mitchell Clayton

(507) 284-2698

Clayton.Mitchell@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20548619

Mayo Clinic Footer